Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01997229) enrolled 125 people with myasthenia gravis — a condition that affects muscle strength and control. Sixty-two participants were assigned to receive eculizumab and 63 received a placebo (an inactive treatment used for comparison). The main thing the trial was measuring was any change in day-to-day functioning over 26 weeks, using a tool called the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which captures how the condition affects routine tasks like eating, speaking, and breathing. The reported data shows that results were analysed using a "worst-rank" method. In this approach, all 125 participants were given a rank between 1 and 125 — where a rank of 1 represented the best reported outcome and a rank of 125 represented the worst. The eculizumab group received an average rank of 56.6, while the placebo group received an average rank of 68.3. A lower average rank in this system indicates a relatively better position within the group as a whole. No other outcome measures were included in the structured results data submitted to ClinicalTrials.gov, so no further figures can be reported here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 29066163) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Myasthenia Gravis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older (male or female)
- You have been diagnosed with Myasthenia Gravis (MG), confirmed by a blood test showing specific antibodies (anti-AChR), plus at least one other test or sign of the condition, such as a nerve/muscle function test, a medication response test, or improvement with MG medication
- Your MG symptoms are rated as moderate to severe (Class II to IV) based on a standard MG classification system, as assessed at your screening visit
- Your MG symptoms are significantly affecting your daily life, with a symptom score of 6 or higher on a standard scale (MG-ADL) at both your screening and start-of-treatment visits
- You have tried at least two medications that suppress the immune system and they did not work well enough, OR you have tried at least one such medication without success and you currently need regular plasma exchange or intravenous immunoglobulin (IVIg) treatments to manage your condition
Who may not be able to join:
- You have a history of a thymoma (a tumor of the thymus gland) or any other thymus-related tumor
- You have had your thymus gland removed within the last 12 months before screening
- Your MG symptoms are very mild (Class I) or you are currently in a severe MG crisis (Class V) at the time of screening
- You have received a medication called rituximab within the last 6 months before screening
- You have received IVIg or plasma exchange treatment within the 4 weeks before your start-of-treatment visit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.